Summary
The India Oral Contraceptive Pills Market is analyzed by product type, distribution channel, end user, and regional demand patterns, covering market size, key growth drivers, competition, and future outlook.
Market Overview
India Oral Contraceptive Pills Market Overview
The India Oral Contraceptive Pills Market was valued at USD 463.2 Mn in 2017 and grew at a CAGR of 6.5% during 2017–2023. The market is further expected to reach USD 1062.5 Mn by 2029, expanding at a projected CAGR of 7.9% over 2023–2029. The industry remains moderately fragmented, with the presence of several large and established players operating in the market. Future growth is expected to be driven by increasing awareness around women’s health and gynecological care, along with continued efforts to control total fertility rate (TFR) and manage population growth in the country.
Taxonomy
India Oral Contraceptive Pills Market Ecosystem
India Oral Contraceptive Pills Market Size (in USD Mn), 2017-2023
India’s Oral Contraceptive Pills (OCP) market recorded steady growth at a CAGR of 6.5% during 2017–2023, reaching a market value of USD 674.9 Mn. This expansion was driven by the rising adoption of contraceptive pills as a method of birth control, with usage increasing from around 4% in 2018 to over 5% in 2021. Market growth was further supported by proactive government measures that improved awareness and expanded the availability of pills at subsidized prices, making them more accessible and affordable. In addition, rising internet and mobile penetration across the country has played an important role in spreading awareness about contraceptive methods and the prevention of unwanted pregnancies. The market has also benefited from the broader global push toward family planning under the Sustainable Development Goals, where contraception is recognized as an important tool for moderating population growth.
India Oral Contraceptive Pills Industry Analysis
India Oral Contraceptive Pills Market Segmentation, 2023
India Oral Contraceptive Pills Market by Product Type (in revenue %), 2023
The Oral Contraceptive Pills market is primarily segmented into Combined Oral Contraceptives (COC) and Emergency Contraceptive Pills (ECP), with COC dominating the market with a substantial 81.2% share, valued at USD 548.4 Mn. In contrast, ECP accounts for the remaining 18.8% share, valued at USD 126.5 Mn. The relatively lower share of ECP is due to the potential side effects associated with its use, especially as it is consumed within 72 hours of unprotected sexual activity and excessive use may lead to serious health complications. Both COC, including POP, and ECP are hormonal contraceptives, but COC is typically taken on a regular 21- or 28-day basis depending on the menstrual cycle and physician guidance. The strong market position of COC is driven by its high contraceptive efficacy, predictable daily usage, and additional health-related benefits beyond contraception.
India Oral Contraceptive Pills Market by regional demography (in revenue %), 2023
The Urban-Rural segmentation of the India OCP Market presents an interesting pattern, with Rural India accounting for the larger share at 54.5%, valued at USD 368.1 Mn, while Urban India represents the remaining 45.5%, valued at USD 306.8 Mn. This dominance of rural demand is not driven by stronger healthcare, education, or economic conditions, but rather by targeted government interventions that have improved accessibility and affordability. Initiatives such as Jan Aushadhi Kendras have expanded the availability of low-cost contraceptive pills, while awareness campaigns led by ASHA workers through door-to-door outreach have strengthened adoption in rural areas. In addition, government subsidies have further supported affordability. In contrast, although urban regions benefit from better healthcare infrastructure, education, economic conditions, and greater confidentiality, consumers there often prefer alternative contraceptive methods over oral contraceptive pills.
India Oral Contraceptive Pills Future Market Size
Looking ahead, the India OCP Market is expected to witness strong growth, with forecasts indicating a steady CAGR of 7.9% from 2023 to 2029F, taking the market value to USD 1,062.5 Mn by 2029F. This growth is likely to be supported by government-run schemes, continued efforts toward population control beyond the SDG 2030 agenda, wider awareness through modern technology, and rising investment in health infrastructure. In addition, several states, including Uttar Pradesh, are introducing schemes that encourage population control by promoting the adoption of birth control methods across communities, which is expected to further support market expansion.
India Oral Contraceptive Pills Market Company Profile
| Company Name | Establishment year | Description |
|---|---|---|
Mankind | 1995 | Mankind is a public pharmaceutical company headquartered in Delhi. It is Largest pharmaceutical company of India (by sales), generating a revenue of INR 87.49 Bn (2023). Its revenue from the Oral Contraceptive Market (under gynecology) in India contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. |
Cipla | 1935 | Cipla is the Indian multinational public pharmaceutical company headquartered in Mumbai. With its presence in over 80 countries, making 1500 products available, Cipla generated a total revenue of INR 227 Bn (2023). Its revenue from the Oral Contraceptive Market (under gynecology) in India contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. |
Sun Pharma | 1983 | Sun Pharmaceutical Industries Limited is the Indian multinational public pharmaceutical company headquartered in Mumbai. With its presence in over 80 countries, Sun Pharma generated a total revenue of INR 445.2 Bn (2023). Its revenue from the Oral Contraceptive Market (under gynecology) in India contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. |
Piramal Pharma | 2020 | Piramal is the Indian multinational public pharmaceutical company headquartered in Mumbai. With its distribution facilities in over 100 countries, Piramal Pharma generated a total revenue of INR 147.1 Bn (2023). Its revenue from the Oral Contraceptive Market (under gynecology) in India contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. |
Zydus | 1952 | Zydus Lifesciences Ltd, earlier known as Cadilla Healthcare Ltd. is the Indian multinational public pharmaceutical company headquartered in Ahmedabad. With its distribution facilities in over 50 countries, Piramal Pharma generated a total revenue of INR 2.51Bn (2023). Its revenue from the Oral Contraceptive Market (under gynecology) in India contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. |
India Oral Contraceptive Pills Market Macro Indicators
India’s GDP has experienced an Increasing growth to USD 3.7 Trillion in 2023, with a decline during pandemic financial year. And decline in inflation further points to increase in purchasing power of the people, both lead to increase in the real income for the people, spilling over to more productive activities such as education and health.
Latest census data (2011) points towards over 73% literacy rate for the whole nation with female lagging at ~65%. But the rate for female literacy has increased to over 70% in a recent report by NSO. Educating people, particularly woman would lead to increase in awareness about the pertaining issues, including Population control and family planning.
India has over 692.0 million internet users with mobile penetration rate is anticipated to be over 85% in 2026, this would lead to access to information without outside help, and to remote places in India. Awareness about family planning would further lead to awareness about OCP and other pregnancy preventive methods, fueling India’s journey to surpassing SDG.
Frequently Asked Questions
Find quick answers to common questions about the India Oral Contraceptive Pills Market